Use of serum biomarkers in a diagnostic test for irritable bowel syndrome

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 8, 2009, Pages 834-842

  Lembo, A J ^b   Neri, B ^a   Tolley, J ^a   Barken, D ^a   Carroll, S ^a   Pan, H ^a  

^a Prometheus Laboratories   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASCA IMMUNOGLOBILIN A; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CBIR 1 ANTIBODY; INTERLEUKIN 1BETA; NEUTROPHIL CYTOPLASMIC ANTIBODY; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; FEMALE; GROWTH RELATED ONCOGENE ALPHA; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ACUTE-PHASE PROTEINS; ADOLESCENT; ADULT; AGED; ALGORITHMS; BIOLOGICAL MARKERS; BRAIN-DERIVED NEUROTROPHIC FACTOR; COHORT STUDIES; CYTOKINES; FEMALE; HUMANS; IMMUNOGLOBULIN ISOTYPES; IRRITABLE BOWEL SYNDROME; LIPOCALINS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; SENSITIVITY AND SPECIFICITY; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSGLUTAMINASES; YOUNG ADULT;

EID: 62849121718     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.03975.x     Document Type: Article

References (41)

1. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006 130 : 1480 91.
2. Saito YA, Schoenfeld P, Locke GR III. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002 97 : 1910 5.
3. Owyang C. Irritable bowel syndrome. In : Fauci AS, Braunwald E, Kasper DL, eds. Harrison's Principles of Internal Medicine, 17th edn. New York : McGraw-Hill Medical, 2008 : 1899 903.
4. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004 292 : 852 8.
5. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002 97 (Suppl 11 S7 26.
6. Frissora CL, Koch KL. Symptom overlap and comorbidity of irritable bowel syndrome with other conditions. Curr Gastroenterol Rep 2005 7 : 264 71.
7. Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharmacol Ther 1997 11 : 3 15.
8. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002 123 : 2108 31.
9. Sanders DS, Carter MJ, Hurlstone DP, et al. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet 2001 358 : 1504 8.
10. Hulisz D. The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Manag Care Pharm 2004 10 : 299 309.
11. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006 130 : 1377 90.
12. Cash BD, Chey WD. Diagnosis of irritable bowel syndrome. Gastroenterol Clin North Am 2005 34 : 205 20, vi.
13. American Gastroenterological Association. American Gastroenterological Association medical position statement: irritable bowel syndrome. Gastroenterology 2002 123 : 2105 7.
14. Tornblom H, Abrahamsson H, Barbara G, et al. Inflammation as a cause of functional bowel disorders. Scand J Gastroenterol 2005 40 : 1140 8.
15. Aerssens J, Camilleri M, Talloen W, et al. Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008 6 : 194 205.
16. Ohama T, Hori M, Sato K, Ozaki H, Karaki H. Chronic treatment with interleukin-1beta attenuates contractions by decreasing the activities of CPI-17 and MYPT-1 in intestinal smooth muscle. J Biol Chem 2003 278 : 48794 804.
17. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995 332 : 1351 62.
18. Imada A, Ina K, Shimada M, et al. Coordinate upregulation of interleukin-8 and growth-related gene product-alpha is present in the colonic mucosa of inflammatory bowel. Scand J Gastroenterol 2001 36 : 854 64.
19. Boesmans W, Gomes P, Janssens J, Tack J, Vanden BP. Brain-derived neurotrophic factor amplifies neurotransmitter responses and promotes synaptic communication in the enteric nervous system. Gut 2008 57 : 314 22.
20. Schnydrig S, Korner L, Landweer S, et al. Peripheral lipopolysaccharide administration transiently affects expression of brain-derived neurotrophic factor, corticotropin and proopiomelanocortin in mouse brain. Neurosci Lett 2007 429 : 69 73.
21. Wen Z, Fiocchi C. Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis? Clin Dev Immunol 2004 11 : 195 204.
22. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004 113 : 1296 306.
23. Kraus H. Gluten glossary. 2008. Available from: http://members.cox.net/ hal.kraus/glossary.htm. Accessed: Jan. 21, 2009.
24. Tonutti E, Visentini D, Bizzaro N, et al. The role of antitissue transglutaminase assay for the diagnosis and monitoring of coeliac disease: a French-Italian multicentre study. J Clin Pathol 2003 56 : 389 93.
25. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008 7 : 411 25.
26. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S. TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem 2003 278 : 36005 12.
27. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007 40 : 1 16.
28. Chicheportiche Y, Fossati-Jimack L, Moll S, Ibnou-Zekri N, Izui S. Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory pathologies. Biochem Biophys Res Commun 2000 279 : 162 5.
29. Mulder AH, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CG. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993 17 : 411 7.
30. Vidrich A, Lee J, James E, Cobb L, Targan S. Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. J Clin Immunol 1995 15 : 293 9.
31. Meijer MJ, Mieremet-Ooms MA, van Hogezand RA, Lamers CB, Hommes DW, Verspaget HW. Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol 2007 13 : 2960 6.
32. Gwira JA, Wei F, Ishibe S, Ueland JM, Barasch J, Cantley LG. Expression of neutrophil gelatinase-associated lipocalin regulates epithelial morphogenesis in vitro. J Biol Chem 2005 280 : 7875 82.
33. Playford RJ, Belo A, Poulsom R, et al. Effects of mouse and human lipocalin homologues 24p3/lcn2 and neutrophil gelatinase-associated lipocalin on gastrointestinal mucosal integrity and repair. Gastroenterology 2006 131 : 809 17.
34. Breiman L. Random Forests. Mach Learn 2001 45 : 5 32.
35. International Foundation for Functional gastrointestinal Disorders. IBS in the Real World Survey. Summary findings. 2007. Available from: http://aboutconstipation.org/pdfs/IBSRealWorld.pdf. (accessed 21 January 2009).
36. Esteva H, Marchevsky A, Nunez T, Luna C, Esteva M. Neural networks as a prognostic tool of surgical risk in lung resections. Ann Thorac Surg 2002 73 : 1576 81.
37. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol 2007 61 : 120 9.
38. Mello G, Parretti E, Ognibene A, et al. Prediction of the development of pregnancy-induced hypertensive disorders in high-risk pregnant women by artificial neural networks. Clin Chem Lab Med 2001 39 : 801 5.
39. Selaru FM, Xu Y, Yin J, et al. Artificial neural networks distinguish among subtypes of neoplastic colorectal lesions. Gastroenterology 2002 122 : 606 13.
40. Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol 2002 97 : 2812 9.
41. El-Serag HB, Pilgrim P, Schoenfeld P. Systemic review: natural history of irritable bowel syndrome. Aliment Pharmacol Ther 2004 19 : 861 70.